Pfizer announces deal with Canada for experimental COVID-19 vaccine
FILE PHOTO: A man walks past a sign outside Pfizer Headquarters in the Manhattan borough of New York City, New York, U.S., July 22, 2020. REUTERS/Carlo Allegri
OTTAWA– Pharmaceutical giant Pfizer and German biotech firm BioNTech SE on Wednesday said they had signed a deal to supply Canada with an experimental coronavirus vaccine.
Deliveries of the BNT162 mRNA-based vaccine candidate are planned over the course of 2021, subject to clinical success and Health Canada approval, the two companies said in a statement. They did not reveal financial details.
Separately, the Canadian government said it would make an announcement on the next steps in procuring vaccines at 10 a.m. ET on Wednesday.
There are no approved vaccines for the illness caused by the new coronavirus, but 19 vaccines are being tested in humans around the world.
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
